2. Signaling Pathways
  3. PROTAC
  4. PROTACs
  5. PROTACs Isoform
  6. PROTACs Degrader

PROTACs Degrader

PROTACs Degraders (38):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-162723
    FOSL1 degrader 1 99.47%
    FOSL1 degrader 1 (4) is a T-5224-PROTAC, potently degrade FOSL1 (AP-1) to suppress cancer stemness gene expression in HNSCC. FOSL1 degrader 1 (4) effectively eliminate HNSCC cancer stem cells to inhibit tumor growth through degrading FOSL1. FOSL1 degrader 1 (4) displays around 30- to 100-fold increased potency over T-5224 (Pink: T-5224 (HY-12270); Black: Linker (HY-130200); Blue: Pomalidomide (HY-10984)).
    FOSL1 degrader 1
  • HY-160415A
    WD6305 TFA 98.47%
    WD6305 TFA is a potent METTL3-targeted PROTAC degrader. WD6305 TFA selectively reduces the METTL3 and METTL14 complex. WD6305 TFA inhibits m6A modification and the proliferation of AML cells and promotes apoptosis. WD6305 TFA can be used for the research of leukemic.
    WD6305 TFA
  • HY-156366
    SNX7886 2924557-42-4 99.97%
    SNX7886 is a potent protac degrader of CDK8/19. SNX7886 degrades CDK 8 and CDK 19 with 90% and 80% degradation in 293 cells, respectively.
    SNX7886
  • HY-162362
    MS8709
    MS8709 (compound 10), a potential anticancer therapeutic, is a first-in-class G9a/GLP PROTAC degrader. MS8709 is based on G9a/GLP inhibitor UNC0642 and recruits the von Hippel Lindau (VHL) E3 ligase (Red: G9a/GLP inhibitor UNC0642; Blue: VHL ligand; Black: linker).
    MS8709
  • HY-161176
    PROTAC KRAS G12D degrader 1
    PROTAC KRAS G12D degrader 1 is a potent, rapid, and selective degrader of protac KRASG12D with DC50 of 38.06 nM. PROTAC KRAS G12D degrader 1 showes significant antitumor efficacy.
    PROTAC KRAS G12D degrader 1
  • HY-155361
    PROTAC BRD9 Degrader-7 99.29%
    PROTAC BRD9 Degrader-7 is an orally active and selective degrader of BRD9 with a DC50 of 1.02 nM. PROTAC BRD9 Degrader-7 has superior oral activity with a Cmax of 3436.95 ng/mL.
    PROTAC BRD9 Degrader-7
  • HY-149862
    ARD-2051 2632305-17-8 98.19%
    ARD-2051 is a potent and orally active androgen receptor (AR) proteolysis-targeting chimera degrader. ARD-2051 achieves DC50 values of 0.6 nM for AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines. ARD-2051 can be used for the research of prostate cancer.
    ARD-2051
  • HY-155102
    PROTAC TG2 degrader-2 99.15%
    PROTAC TG2 degrader-2 (compound 7) is a selective, competitive degrader targeting Transglutaminase 2 (TG2), with Kd > 100 μM. PROTAC TG2 degrader-2 inhibits the cell migration and decreases the level of TG2 in ovarian cancer cells. PROTAC TG2 degrader-2 can be used for ovarian cancer study.
    PROTAC TG2 degrader-2
  • HY-131865
    SJF-1521 2230821-40-4 99.20%
    SJF-1521 is a selective EGFR PROTAC degrader. SJF-1521 contains the EGFR inhibitor lapatinib (HY-50898). SJF-1521 can induce EGFR degradation in OVCAR8 cells.
    SJF-1521
  • HY-162412
    PROTAC AR/AR-V7 degrader-1 2841308-96-9
    PROTAC AR/AR-V7 degrader-1 (27c) is a PROTAC-based and dual AR, AR-V7 degrader, with DC50 values of 2.67 and 2.64 μM for AR and AR-V7, respectively. PROTAC AR/AR-V7 degrader-1 (27c) induces apoptosis (Red: AR antagonist; Blue: E3 ligase ligand; Black: linker).
    PROTAC AR/AR-V7 degrader-1
  • HY-162704
    JMV7048 2871774-88-6
    JMV7048 is an effective PROTAC degrader targeting PXR (Pregnane X Receptor) with a DC50 of 379 nM. JMV7048 induces the polyubiquitination and degradation of PXR protein by recruiting E3 CRBN ubiquitin ligase and the 26S proteasome. JMV7048 significantly enhances the sensitivity of colon cancer stem cells to chemotherapy by reducing the expression of PXR protein in these cells, thereby significantly delaying cancer recurrence in vivo. JMV7048 is composed of the PXR agonist JMV6944 (HY-162738), linker (HY-162736), and Thalidomide 5-fluoride (HY-W087383) (Red: JMV6944; Blue: Thalidomide 5-fluoride ligand; Black: linker).
    JMV7048
  • HY-123961
    SJF-8240 2230821-68-6 99.33%
    SJF-8240 (PROTAC 7) is a proteolysis targeting chimera (PROTAC) degrader. SJF-8240 induces polyubiquitination of c-Met and inhibits the proliferation of GTL16 cells (IC50=66.7 nM).
    SJF-8240
  • HY-131864
    SJF-1528 2230821-38-0 98.90%
    SJF-1528 is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutated EGFR in HeLa cells. SJF-1528 also degrades HER2 (Pink: ligand for target protein (HY-159047); Black: linker Tos-PEG2-CH2-Boc (HY-130532); Blue: ligand for E3 ligase (S,R,S)-AHPC (HY-125845)).
    SJF-1528
  • HY-160502
    CST967 99.33%
    CST967 (Compound 17) is a USP7 PROTAC degrader, and increasing the PROTAC concentration can enhance the degradation rate of USP7. CST967 can be used in cancer research.
    CST967
  • HY-161173
    PROTAC SOS1 degrader-5 2836273-61-9
    PROTAC SOS1 degrader-5 (compound 4) is a potent PROTAC SOS1 degrader, with the DC50 of 13 nM. PROTAC SOS1 degrader-5 strongly inhibits NCI-H358 cells proliferation with an IC50 of 5 nM.
    PROTAC SOS1 degrader-5
  • HY-158381
    PROTAC PTP1B degrader 1
    PROTAC PTP1B degrader 1 (compound 75) is a CRBN-based PTP1B PROTAC degrader, with DC50 values of 0.2 μM (48 h) and 0.05 μM (72 h) (Red: PTP1B ligand Oleanolic acid (HY-N0156); Black: linker; Blue: CRBN ligand).
    PROTAC PTP1B degrader 1
  • HY-148521
    PROTAC FLT3/CDK9 degrader-1
    PROTAC FLT3/CDK9 degrader-1 is a potent FLT3 and CDK9 dual PROTAC degrader. PROTAC FLT3/CDK9 degrader-1 induces apoptosis and effective degradation of target proteins FLT3 and CDK9. PROTAC FLT3/CDK9 degrader-1 has the potential for the research of FLT3-ITD mutated AML.
    PROTAC FLT3/CDK9 degrader-1
  • HY-153880
    KRAS degrader-1 2795275-59-9
    KRAS degrader-1 (compound 1) is a potent KRAS degrader. KRAS degrader-1 target specific proteins for degradation through the autophagy-lysosomal degradation pathway.
    KRAS degrader-1
  • HY-163582
    PROTAC SOS1 degrader-7 3036155-26-4
    PROTAC SOS1 degrader-7 (Example 15) is a SOS1 PROTAC degrader. PROTAC SOS1 degrader-7 has anti-tumor activity . (Pink: SOS1 ligand (HY-163583); Black: linker (HY-163584); Blue: E3 ligase ligand (HY-W454906)).
    PROTAC SOS1 degrader-7
  • HY-162608
    PROTAC JAK1 degrader 1 3052553-20-2
    PROTAC JAK1 degrader 1 degrader 1 (compound 10c) is an effective and selective PROTAC JAK1 degrader with a DC50 of 214 nM. PROTAC JAK1 degrader 1 has antitumor activity. (Structure Note: PINK, JAK1 ligand 1 (HY-10961); Blue, VHL ligand Thalidomide (HY-14658); Black, linker).
    PROTAC JAK1 degrader 1